RxDoctor Payments Data

Mark Coronel, MD

Internal Medicine · Manorville, NYNPI 1346416963

Payments from drug & device makers

$682in general payments, 2019–2025

Across 26 payments — averaging $26.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$256
  • E.r. Squibb & Sons, L.L.C.$135
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$133
  • Takeda Pharmaceuticals U.S.A., Inc.$59
  • Madrigal Pharmaceuticals$29
  • Johnson & Johnson$27
  • plus $44 from 2 others

What the payments were for

  • Food & beverage$682100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$682 in reported general payments places this provider in the 65th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$541,177
Medicare patients
1,148
Services billed
2,244

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab15$366,031
OcalivaObeticholic Acid29$294,694
Humira(Cf) PenAdalimumab12$100,920
XifaxanRifaximin32$88,400
CreonLipase/Protease/Amylase27$72,925
LinzessLinaclotide43$44,915
ViberziEluxadoline17$26,264
Mesalamine30$19,887
VireadTenofovir Disoproxil Fumarate12$14,741
SutabSod Sulf/Pot Chloride/Mag Sulf74$11,786
Lubiprostone30$8,614
Pantoprazole Sodium497$6,676
Dexlansoprazole DrDexlansoprazole24$6,064
Ursodiol30$6,015
Breo ElliptaFluticasone/Vilanterol11$4,550

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$27$366,03115 claims
AbbVieCreon, Linzess, Viberzi$256$144,10387 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$133$88,40032 claims
GileadViread$22$14,74112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Manorville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →